 Cytokinetics Incorporated NASDAQ: CYTK shares continue to move forward after it announced positive REDWOOD-HCM Phase 2 data for CK-274 and garnered favorable comments from analysts. On Tuesday, Barclays raised Cytokinetics price target to 40 from 28, equivalent to an upside of around 30, and kept an Overweight rating. 